Department of Immunology and Infectious Diseases and Department of Molecular Metabolism, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Harvard T.H. Chan Microbiome in Public Health Center, Boston, Massachusetts, USA.
J Clin Invest. 2022 Feb 15;132(4). doi: 10.1172/JCI155101.
The importance of the microbiota in the development of colorectal cancer (CRC) is increasingly evident, but identifying specific microbial features that influence CRC initiation and progression remains a central task for investigators. Studies determining the microbial mechanisms that directly contribute to CRC development or progression are revealing bacterial factors such as toxins that contribute to colorectal carcinogenesis. However, even when investigators have identified bacteria that express toxins, questions remain about the host determinants of a toxin's cancer-potentiating effects. For other cancer-correlating bacteria that lack toxins, the challenge is to define cancer-relevant virulence factors. Herein, we evaluate three CRC-correlating bacteria, colibactin-producing Escherichia coli, enterotoxigenic Bacteroides fragilis, and Fusobacterium nucleatum, for their virulence features relevant to CRC. We also consider the beneficial bioactivity of gut microbes by highlighting a microbial metabolite that may enhance CRC antitumor immunity. In doing so, we aim to elucidate unique and shared mechanisms underlying the microbiota's contributions to CRC and to accelerate investigation from target validation to CRC therapeutic discovery.
肠道微生物群在结直肠癌(CRC)发展中的重要性日益明显,但确定影响 CRC 起始和进展的特定微生物特征仍然是研究人员的一项核心任务。确定直接促进 CRC 发生和发展的微生物机制的研究揭示了细菌因子,如导致结直肠发生癌变的毒素。然而,即使研究人员已经确定了表达毒素的细菌,关于毒素促进癌症发生的宿主决定因素的问题仍然存在。对于缺乏毒素的其他与癌症相关的细菌,挑战在于定义与癌症相关的毒力因子。在此,我们评估了三种与 CRC 相关的细菌,即产细胞毒素大肠埃希菌、产肠毒素脆弱拟杆菌和具核梭杆菌,以评估它们与 CRC 相关的毒力特征。我们还通过强调一种可能增强 CRC 抗肿瘤免疫的微生物代谢物来考虑肠道微生物的有益生物活性。这样,我们旨在阐明微生物群促进 CRC 的独特和共同机制,并加速从靶标验证到 CRC 治疗发现的研究。